596 related articles for article (PubMed ID: 22634229)
1. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
3. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.
González C; Herradón E; Abalo R; Vera G; Pérez-Nievas BG; Leza JC; Martín MI; López-Miranda V
Diabetes Metab Res Rev; 2011 May; 27(4):331-40. PubMed ID: 21309057
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.
Fernández-López D; Martínez-Orgado J; Nuñez E; Romero J; Lorenzo P; Moro MA; Lizasoain I
Pediatr Res; 2006 Aug; 60(2):169-73. PubMed ID: 16864698
[TBL] [Abstract][Full Text] [Related]
7. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
8. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
Sánchez AJ; González-Pérez P; Galve-Roperh I; García-Merino A
Biochem Pharmacol; 2006 Dec; 72(12):1697-706. PubMed ID: 17007821
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
10. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
12. Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.
Rizzo V; Carletti F; Gambino G; Schiera G; Cannizzaro C; Ferraro G; Sardo P
Epilepsy Res; 2014 Dec; 108(10):1711-8. PubMed ID: 25458534
[TBL] [Abstract][Full Text] [Related]
13. WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice.
Zhao Y; Liu Y; Zhang W; Xue J; Wu YZ; Xu W; Liang X; Chen T; Kishimoto C; Yuan Z
Eur J Pharmacol; 2010 Dec; 649(1-3):285-92. PubMed ID: 20868672
[TBL] [Abstract][Full Text] [Related]
14. Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period.
Rudenko V; Rafiuddin A; Leheste JR; Friedman LK
Pharmacol Biochem Behav; 2012 Jan; 100(3):474-84. PubMed ID: 22019959
[TBL] [Abstract][Full Text] [Related]
15. Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2.
Payandemehr B; Ebrahimi A; Gholizadeh R; Rahimian R; Varastehmoradi B; Gooshe M; Aghaei HN; Mousavizadeh K; Dehpour AR
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Mar; 57():140-5. PubMed ID: 25448777
[TBL] [Abstract][Full Text] [Related]
16. Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2.
Enayatfard L; Rostami F; Nasoohi S; Oryan S; Ahmadiani A; Dargahi L
Neuromolecular Med; 2013 Sep; 15(3):523-35. PubMed ID: 23794089
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress.
Ganon-Elazar E; Akirav I
Neuropsychopharmacology; 2012 Jan; 37(2):456-66. PubMed ID: 21918506
[TBL] [Abstract][Full Text] [Related]
18. Effect of acute and subchronic administration of (R)-WIN55,212-2 induced neuroprotection and anti inflammatory actions in rat retina: CB1 and CB2 receptor involvement.
Spyridakos D; Papadogkonaki S; Dionysopoulou S; Mastrodimou N; Polioudaki H; Thermos K
Neurochem Int; 2021 Jan; 142():104907. PubMed ID: 33220388
[TBL] [Abstract][Full Text] [Related]
19. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.
Luca T; Di Benedetto G; Scuderi MR; Palumbo M; Clementi S; Bernardini R; Cantarella G
Eur J Pharmacol; 2009 Aug; 616(1-3):16-21. PubMed ID: 19539619
[TBL] [Abstract][Full Text] [Related]
20. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]